



**EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2014. Scientific Opinion on lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL)**

**EFSA Journal**

*Link to article, DOI:*  
[10.2903/j.efsa.2014.3762](https://doi.org/10.2903/j.efsa.2014.3762)

*Publication date:*  
2014

*Document Version*  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

*Citation (APA):*  
EFSA Journal (2014). *EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2014. Scientific Opinion on lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL)*. European Food Safety Authority. EFSA Journal Vol. 12(7) No. 3762  
<https://doi.org/10.2903/j.efsa.2014.3762>

---

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## SCIENTIFIC OPINION

### Scientific Opinion on Lipase from a Genetically Modified Strain of *Aspergillus oryzae* (strain NZYM-FL)<sup>1,2</sup>

#### EFSA Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids (CEF)<sup>3,4</sup>

European Food Safety Authority (EFSA), Parma, Italy

#### ABSTRACT

The food enzyme considered in this opinion is a lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a genetically modified strain of *Aspergillus oryzae*. The genetic modifications do not raise safety concern. The food enzyme contains neither the production organism nor recombinant DNA. The lipase is intended to be used in a number of food manufacturing processes, such as oils, fats and eggs processing. The dietary exposure was assessed on the basis of data retrieved from the EFSA Comprehensive European Food Consumption Database. The food enzyme did not induce gene mutations in bacteria nor chromosome aberrations in human lymphocytes. Therefore, there is no concern with respect to genotoxicity. The systemic toxicity was assessed by means of a 90-day subchronic oral toxicity study in rodents. A No Observed Adverse Effect Level was derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure. The allergenicity was evaluated by searching for similarity of the amino acid sequence to those of known allergens. The Panel considered that the likelihood of food allergic reactions to the enzyme is low and therefore does not raise safety concern. Based on the genetic modifications performed, the manufacturing process, the compositional and biochemical data provided and the toxicological studies, this food enzyme does not raise safety concern under the intended conditions of use.

© European Food Safety Authority, 2014

#### KEY WORDS

food enzyme, lipase, triacylglycerol lipase, EC 3.1.1.3, *Aspergillus oryzae*, genetically modified microorganism

<sup>1</sup> On request from the European Commission, Question No EFSA-Q-2013-00197, adopted on 20 June 2014.

<sup>2</sup> This scientific opinion replaces the previously published summary of the opinion following the provisions of article 12(3) of Regulation (EC) No 1331/2008.

<sup>3</sup> Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt†, Kjetil Svensson, Maria de Fátima Tavares Poças, Fidel Toldrá and Detlef Wölflé. Correspondence: [fip@efsa.europa.eu](mailto:fip@efsa.europa.eu)

<sup>4</sup> The Panel wishes to thank the members of the Working Group on Enzymes: Alain Deschamps, Francis Duchiron, Karl-Heinz Engel, Thomas Haertlé, Torben Hallas-Møller, Lieve Herman, Klaus-Dieter Jany, Philippe Joudrier, Sirpa Kärenlampi, Anna Mehl, Manfred Metzler, Morten Poulsen, Fidel Toldrá, Henk van Loveren, Holger Zorn for the preparatory work on this scientific opinion and EFSA staff: Margarita Aguilera-Gomez, Anna Christodoulidou, Marina Goumenou, Anne Theobald, Rachele Tamburino and Kim Rygaard Nielsen for the support provided to this scientific opinion.

† Deceased

Suggested citation: EFSA CEF Panel (EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids), 2014. Scientific Opinion on lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL). EFSA Journal 2014;12(7):3762, 2 pp. doi:10.2903/j.efsa.2014.3762

Available online: [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal)

## SUMMARY

Following a request from the European Commission, the CEF Panel on Food Contact Material, Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion on the food enzyme lipase (triacylglycerol lipase; EC 3.1.1.3) produced with the genetically modified *Aspergillus oryzae* strain NZYM-FL.

The *A. oryzae* parental strain has a long history of use for the production of food enzymes. It has been modified in order to produce and secrete lipase and to prevent or decrease the production of undesirable secondary metabolites. The genetic modifications do not raise safety concern.

The food enzyme contains neither the production organism nor recombinant DNA, given the limits of detection.

The food enzyme has been characterised by determining the temperature and pH optima and the thermo-stability. Its composition is verified by measuring the content of protein, ash, water, heavy metals and Total Organic Solid. The *A. oryzae* parental strain has been modified in order to prevent the production of cyclopiazonic acid and to decrease the potential production of kojic acid. The absence of cyclopiazonic acid,  $\beta$ -nitropropionic acid and kojic acid was demonstrated, given the limits of detection.

The food enzyme is intended to be used in a number food manufacturing processes, such as oils, fats and eggs processing. The typical uses and the use levels recommended for specific food processes have been provided.

The estimated dietary exposure was calculated on the basis of data retrieved from the EFSA Comprehensive European Food Consumption Database.

The genotoxicity of the food enzyme was assessed by means of two *in vitro* assays (gene mutations in bacteria and chromosome aberrations in human lymphocytes). The food enzyme, produced with the genetically modified *A. oryzae* strain NZYM-FL, did not induce gene mutations in bacteria with or without metabolic activation when tested under the conditions employed in the study as presented by the applicant. Neither did it induce chromosome aberrations in cultured human blood lymphocytes under the test conditions employed for this study. The systemic toxicity was assessed by means of a 90-day subchronic oral toxicity study in rodents. A No Observed Adverse Effect Level (NOAEL) was derived, which compared with the dietary exposure results in a sufficiently high Margin of Exposure.

The CEF Panel considers that the likelihood of food allergic reactions to this lipase produced with this genetically modified strain of *A. oryzae* is low and therefore does not raise safety concern.

Based on the genetic modifications performed, the manufacturing process, the compositional and biochemical data provided and the toxicological studies, the Panel concluded that this food enzyme does not raise safety concern under the intended conditions of use.

## TABLE OF CONTENTS

Abstract .....	1
Summary .....	2
Table of contents .....	3
Background as provided by the European Commission.....	4
Terms of reference as provided by the European Commission.....	4
Assessment .....	5
1. Introduction.....	5
2. Information on existing authorisations and evaluations.....	5
3. Technical data .....	6
3.1. Identity of the food enzyme .....	6
3.2. Chemical parameters.....	6
3.3. Properties of the food enzyme .....	8
3.4. Information on the source materials.....	8
3.4.1. Information relating to the genetically modified microorganism .....	8
3.5. Manufacturing process.....	9
3.5.1. Information relating to the fermentation process.....	9
3.5.2. Information relating to the downstream processing.....	9
3.6. Reaction and fate in food.....	10
3.7. Case of need and intended conditions of use .....	10
4. Dietary exposure .....	11
5. Toxicological data.....	11
6. Allergenicity.....	12
7. Discussion .....	13
Conclusions .....	13
Documentation provided to EFSA .....	13
References .....	14
Abbreviations .....	15

## BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

Only food enzymes included in the Union list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7 (2) of Regulation (EC) No 1332/2008<sup>5</sup> on food enzymes. According to Regulation (EC) No 1332/2008 on food enzymes, a food enzyme which falls within the scope of Regulation (EC) No 1829/2003<sup>6</sup> on genetically modified food and feed should be authorised in accordance with that Regulation as well as under this Regulation.

An application has been introduced by the company Novozymes A/S for the authorisation of the food enzyme lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL).

Following the requirements of Article 12.1 of Commission Regulation (EC) No 234/2011<sup>7</sup> implementing Regulation (EC) No 1331/2008<sup>8</sup>, the Commission has verified that the application falls within the scope of the food enzyme Regulation and contains all the elements required under Chapter II of that Regulation.

## TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

The European Commission requests the European Food Safety Authority to carry out the safety assessment on the food enzyme lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL) in accordance with the article 17.3 of Regulation (EC) No 1332/2008 on food enzymes.

---

5 Regulation (EC) No 1332/2008 of the European Parliament and of the Council of 16 december 2008 on Food Enzymes and Amending Council Directive 83/417/EEC, Council Regulation (EC) No 1493/199, Directive 2000/13/EC, Council Directive 2001/112/EC and Regulation (EC) No 258/97. OJ L 354, 31.12.2008, p. 7-15.

6 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed. OJ L 268, 18.10.2003 p. 1-23.

7 Commission Regulation (EU) No 234/2011 of 10 March 2011 implementing Regulation (EC) No 1331/2008 of the European Parliament and of the Council establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 64, 11.03.2011, p. 15-24.

8 Regulation (EC) No 1331/2008 of the European Parliament and of the Council of 16 December 2008 establishing a common authorisation procedure for food additives, food enzymes and food flavourings. OJ L 354, 31.12.2008, p. 1-6.

## ASSESSMENT

### 1. Introduction

Before January 2009 food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009 the Regulation (EC) No 1332/2008 on food enzymes entered into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. The Regulation (EC) No 1331/2008 established Union procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall only be authorised if it is demonstrated that:

- (i) it does not pose a safety concern to the health of the consumer at the level of use proposed;
- (ii) there is a reasonable technological need, and
- (iii) its use does not mislead the consumer.

All food enzymes currently on the EU market and intended to remain on that market as well as all new food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and an approval via a Union list.

The Guidance on submission of a dossier on a food enzyme for evaluation by EFSA (EFSA, 2009) lays down the administrative, technical and toxicological data required.

In the case of enzymes produced with genetically modified microorganisms (GMM) the guidance on the risk assessment of GMM and their products intended for food and feed use (EFSA GMO Panel, 2011) applies.

The assessment of a GMM aims to evaluate the safety of the enzyme preparation related to the genetic modifications. This starts from the evaluation of the safety of the parental/recipient and donor strains, e.g. regarding their capability to produce undesirable metabolites. It also includes the assessment of the genetic modifications, specifically of the introduction of genes of concern and the genetic stability. Finally, the presence of the production organism and its recombinant DNA in the final product is assessed. Special attention is paid to the presence of any recombinant genes of concern (e.g. antibiotic resistance genes), introduced during the development of the production strain. If the absence of the production strain and the recombinant DNA has been confirmed, no extensive environmental risk assessment of the enzyme product is required.

The following evaluation applies to the lipase (triacylglycerol lipase; EC 3.1.1.3) produced with a genetically modified strain of *A.oryzae* strain NZYM-FL.

### 2. Information on existing authorisations and evaluations

The applicant reports that the Danish and French authorities have evaluated and authorised the use of the food enzyme produced with the genetically modified *A. oryzae* strain NZYM-FL for oil and egg yolk processing. The Danish authority also provides the conditions of use, including the dosage to be added to specific foods that were up to a level of 40 LU/kg egg yolk and up to 0.5 KLU<sup>9</sup>/kg of oil.

---

<sup>9</sup> (K)LU = (Kilo) Lipase Units (see Section 3.3)

### 3. Technical data

#### 3.1. Identity of the food enzyme

IUBMB nomenclature:	Triacylglycerol lipase
Systematic name:	Triacylglycerol acylhydrolase
Synonym:	Lipase
IUBMB No:	EC 3.1.1.3
CAS No:	9001-62-1
EINECS No:	232-619-9.

#### 3.2. Chemical parameters

The lipase produced with the genetically modified *A. oryzae* strain NZYM-FL is a single polypeptide chain of 274 amino acids. The molecular mass derived from the amino acid sequence was calculated to be 29.9 kDa.

Data on the chemical parameters and the protein homogeneity status of the food enzyme have been provided for four food enzyme batches, three batches to be used for commercialisation and one batch (PPW 7023) used for the toxicological tests (Table 1).

The average Total Organic Solids (TOS) of the four food enzyme batches was 9.3 % (w/w); the values ranged from 8.1 to 10.1 % (Table 1). TOS is a calculated value derived from 100 % minus % water minus % ash. The four food enzyme batches presented in Table 1 are concentrates without any added diluents.

The average specific activity of the four food enzyme batches expressed as ratio enzyme activity/mg TOS was 0.217 KLU/mg TOS; the values ranged from 0.192 to 0.237 KLU/mg TOS (Table 1). Considering the low variability of the activities as well as the specific activities in the four food enzyme batches, the average activity/mg TOS value of 0.217 KLU/mg TOS was used for subsequent calculations.

*A. oryzae*, as a species, is known to have the potential to produce undesirable secondary metabolites such as cyclopiazonic acid (CPA),  $\beta$ -nitropropionic acid (NPA) and kojic acid (KA) (Blumenthal, 2004). Accordingly, these mycotoxins must be checked in the final food enzyme from *A. oryzae* (FAO/WHO, 2006). *A. oryzae* as a species belongs to the *Aspergillus flavus* group which is known to have a gene cascade for the biosynthesis of aflatoxins, but under any known fermentation conditions, *A. oryzae* strains never produced aflatoxins (Blumenthal, 2004; Lee et al., 1991). The parental strain has been modified by  $\gamma$ -irradiation mutagenesis, resulting in the deletion of gene clusters required for the synthesis of the mycotoxins cyclopiazonic acid (*cpa*) and aflatoxin (*afl*). UV irradiation mutagenesis resulted in a reduced potential (15 % of the original) to produce kojic acid. None of these three species-specific mycotoxins (CPA, NPA and KA) were detected in the food enzyme (Table 1) by mass spectrometry (LC-MS/MS).

The protein homogeneity status of the food enzyme was also investigated by SDS-PAGE analysis. The apparent molecular mass based on this technique is about 36 kDa (compared to the calculated molecular mass of 29.9 kDa). According to the applicant, this is most likely due to glycosylation, a common feature of proteins of *Aspergillus*. The gels presented for the four food enzyme batches consistently showed a single protein band corresponding to a molecular mass of about 36 kDa.

The food enzyme was tested for other enzyme activities, i.e. alpha-amylase,  $\beta$ -glucanase, protease and cellulase activities, which were below the detection limits of the employed methods, except for the  $\beta$ -glucanase activity (Table 1).

**Table 1:** Compositional data of the food enzyme

Parameter	Unit	Batches			
		LMF 0006	LMF 0009	LMF 0010	PPW 7023 <sup>(a)</sup>
Lipase activity	KLU/g batch <sup>(b)</sup>	21.1	22.0	18.7	18.2
Protein	% (w/w)	8.0	9.1	7.7	7.5
Ash	% (w/w)	3.6	3.8	3.4	3.5
Water	% (w/w)	86.3	86.9	88.5	87.0
Total Organic Solids (TOS) <sup>(c)</sup>	% (w/w)	10.1	9.3	8.1	9.5
Activity/mg TOS	KLU/mg TOS	0.209	0.237	0.231	0.192
Pb	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
As	mg/kg batch	0.26	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Cd	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Hg	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Antimicrobial activity		ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Production strain	CFU per g batch	NA <sup>(e)</sup>	NA <sup>(e)</sup>	NA <sup>(e)</sup>	ND <sup>(d)</sup>
Cyclopiazonic acid	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Kojic acid	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
$\beta$ -nitropropionic acid	mg/kg batch	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Antifoam	mg/kg batch	930	950	840	850
Alpha-amylase	KNU(T)/g batch <sup>(f)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
$\beta$ -glucanase	BGU/g batch <sup>(g)</sup>	0.28	0.70	0.40	0.66
Protease	AU(A)/g batch <sup>(h)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>
Cellulase	ECU/g batch <sup>(i)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>	ND <sup>(d)</sup>

(a): Batch used for the toxicological tests.

(b): KLU: Kilo Lipase Units (see Section 3.3).

(c): TOS calculated as 100 % - % water - % ash.

(d): ND: Not detected: below the limits of detections (Pb: 1 mg/kg; As: 0.1 mg/kg; Cd: 0.05 mg/kg; Hg: 0.03 mg/kg; cyclopiazonic acid: 0.01 mg/kg; kojic acid: the limits of detection ranged from 0.01 to 0.04 mg/kg;  $\beta$ -nitropropionic acid: the limits of detection ranged from 0.40 to 1.1 mg/kg; alpha-amylase: 0.30 KNU(T); protease: 0.0011 AU(A)/g; cellulase: 30 ECU/g; antimicrobial activity: inhibition zone diameters  $\leq$  16 mm imply that the antimicrobial activity was absent (FAO/WHO, 2006)).

(e): NA: Not analysed.

(f): KNU(T): Kilo Novo alpha-amylase Units (relative to an internal enzyme standard "T").

(g): BGU: Beta-Glucanase Units.

(h): AU(A): Anson Units (relative to an internal enzyme standard "A").

(i): ECU: Endo-Cellulase Units.

The food enzyme complies with the microbiological criteria as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that *Escherichia coli* and *Salmonella* species are absent in 25 g of sample and total coliforms are not more than 30 CFU (Colony Forming Units) per gram.

The applicant has provided information on the identity of the antifoam agents and the Panel considers the use of these as of no safety concern.



The provided data regarding compositional batch-to-batch-variability are considered sufficient. Table 1 shows that the food enzyme batch PPW 7023 used for the toxicological assays has a similar activity/mg TOS, level of inorganic constituents and amount of antifoam agents in relation to the other three food enzyme batches (LMF). Consequently, this food enzyme batch (PPW 7023) is considered suitable for the toxicological testing.

### 3.3. Properties of the food enzyme

Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols, thus resulting in the generation of free fatty acids, diacylglycerols, monoacylglycerols and glycerol. It also hydrolyses the sn-1-ester linkage of diacylphospholipids resulting in the formation of 2-acyl-1-lysophospholipid and free fatty acid. It does not require any co-factor.

The enzymatic activity is quantified by using a pH-stat titration system and is expressed in Kilo Lipase Units/g (KLU/g). One LU is the amount of enzyme which releases 1  $\mu\text{mol}$  of titratable butyric acid per minute under the given standard conditions (reaction conditions: pH = 7.0, T = 30 °C, reaction time, at least 1.5 minutes). One LU corresponds to the international definition of an enzyme unit. In the assay, tributyrin is used as substrate. Its cleavage results in butyric acid formation, which cause a pH variation. The reaction rate, and therefore the enzyme activity, are determined by measuring the volume of titrant added to the reaction system per minute to keep the pH constant.

The food enzyme has been characterised regarding its activity depending on temperature and pH. The lipase is active at temperatures up to 70 °C (with an optimum at approximately 50 °C at pH 6) and within the pH-range of 4 to 10 (with an optimum of about pH 7 at 30 °C). The thermo-stability of the food enzyme was tested over the range of 15 °C to 90 °C after a pre-incubation at the different temperatures at pH 6 for 30 minutes. The activity itself was measured under standard conditions. The lipase retained its activity at temperatures up to 50 °C. At higher temperatures the food enzyme losses rapidly its activity (at 55 °C, 40 % residual activity, pre-incubation at pH 6 for 30 minutes) and above 70 °C, no activity remains after 30 minutes.

### 3.4. Information on the source materials

#### 3.4.1. Information relating to the genetically modified microorganism

##### 3.4.1.1. Characteristics of the recipient and parental microorganisms

The production organism is the fungus *A. oryzae*. *A. oryzae* strains are not qualified as QPS (Qualified Presumption of Safety) because of the potential of mycotoxin production (EFSA BIOHAZ, 2012). The parental strain, *A. oryzae* A1560, has a long history of use for the production of food enzymes. The recipient strain *A. oryzae* BECh2 has been developed from the parental strain, *A. oryzae* A1560, through a series of modification steps including classical mutagenesis and genetic modification (the latter not described for confidentiality reasons).

The classical mutagenesis steps included  $\gamma$ -irradiation mutagenesis, resulting in the deletion of gene clusters required for the synthesis of the mycotoxins cyclopiazonic acid (*cpa*) and aflatoxin (*afl*), and UV irradiation mutagenesis, resulting in a drastically reduced potential (15 % of the original) to produce kojic acid. A Southern blot analysis confirmed the absence of antibiotic resistance genes which were used during the genetic modification of the recipient strain.

##### 3.4.1.2. Characteristics of the donor organisms

The plasmid vector used for the transformation of the recipient strain contained elements to control the expression of the gene of interest as well as ensure integration of the introduced DNA into the recipient strain chromosome. The DNA introduced into the recipient strain did not contain antibiotic resistance genes.

#### 3.4.1.3. Description of the genetic modification process

The production strain *A. oryzae* NZYM-FL was developed from the recipient strain BECh2 through transformation with a plasmid vector and selection of the transformants on appropriate medium.

The production strain differs from the recipient strain by the synthesis and secretion of lipase.

#### 3.4.1.4. Safety aspects of the genetic modification: Information relating to the GMM and comparison of the GMM with its conventional counterpart

In comparison to the parental strain A1560, the recipient strain has lost the potential to produce cyclopiazonic acid and has a reduced potential to produce kojic acid.

The final production strain NZYM-FL differs from the recipient strain by the synthesis and secretion of lipase.

The presence of the gene encoding lipase in the NZYM-FL strain was verified by Southern blot analysis; this indicated that multiple copies of the full-length gene were integrated in the chromosomal DNA of the recipient. In order to estimate the number of copies, a quantitative real-time PCR was carried out.

Southern analysis of the DNA production strain from three independent enzyme preparation batches at the end of pilot scale fermentation confirmed the genetic stability of the genetic modifications.

The genetic modifications do not raise safety concern.

#### 3.4.1.5. Safety for the environment

Neither the production strain nor its recombinant DNA were detected in the final product (see Section 3.5.2). Accordingly, as the food enzyme belongs to Category 2 of the guidance on risk assessment of genetically modified microorganisms and their products (EFSA GMO Panel, 2011), environmental exposure to the genetically modified microorganism or its DNA is negligible and hence no further environmental risk assessment is required.

### 3.5. Manufacturing process

The manufacturing process includes a fermentation process and downstream processing. A comprehensive dataset related to the manufacturing process including a flow diagram was provided. The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004<sup>10</sup>. According to the applicant the manufacturing process is certified according to Food Safety Systems Certification 22000 (FSSC 22000) and ISO 9001.

#### 3.5.1. Information relating to the fermentation process

The food enzyme is produced by a pure culture in contained submerged fed-batch fermentation with conventional process controls in place. The identity and the purity of the culture are checked at each transfer step from frozen vials to the end of fermentation.

#### 3.5.2. Information relating to the downstream processing

The downstream processing includes recovery, purification and concentration. The food enzyme produced is recovered from the fermentation broth after biomass separation via filtration. Further purification and concentration involve a series of filtration steps, including ultrafiltration and final germ filtration.

---

<sup>10</sup> Regulation (EC) No 852/2004 of the European Parliament and of the Council of 29 April 2004 on the hygiene of food additives. OJ L 226, 25.6.2004, p. 3-21.

The production strain could not be detected in a test volume of 1 g of three independent liquid batches tested in triplicate by liquid culturing in non-selective medium for 4 days (for resuscitation) followed by growth on selective solid agar plates for 4 days at suitable temperature favouring the growth of the production strain. No recombinant DNA was detected starting with 1 g of three samples of the concentrated product before formulation obtained from three independent production batches and tested in triplicate. Analysis was performed by PCR, amplifying the recombinant fragment spanning the deletion of an endogenous gene specific for the strain lineage, introduced in the first genetic modification step of the parental strain.

### 3.6. Reaction and fate in food

Triacylglycerol lipases catalyse the hydrolysis of the ester linkages in triacylglycerols. The hydrolysis of triacylglycerols results in the generation of free fatty acids, diacylglycerols, monoacylglycerols and glycerol. It also hydrolyses the sn-1-ester linkage of diacylphospholipids resulting in the formation of 2-acyl-1-lysophospholipid and free fatty acid.

The data and information provided indicate that the lipase is denatured during processing under the intended use conditions. The food enzyme was tested for other enzyme activities, i.e. alpha-amylase, beta-glucanase, protease and cellulase activities, which were below the detection limits of the employed methods. Therefore, no unintended reaction products from the lipase and any side-activities are to be expected.

### 3.7. Case of need and intended conditions of use

The food enzyme is intended to be used in a number of food manufacturing processes. Typical uses provided by the applicant are listed in Table 2.

**Table 2:** Typical uses and recommended maximum use levels of the food enzyme as provided by the applicant

Process	Recommended dosage of the food enzyme
Oils and fats processing	600 LU/kg of oils/fats, corresponding to 2.8 mg TOS/kg (600 LU/217 LU/mg TOS (217 is the average of four food enzyme batches))
Eggs processing	40 KLU/kg of egg yolks, corresponding to 184 mg TOS/kg (40000 LU/217 LU/mg TOS (217 is the average of the four food enzyme batches))

Its use during the oils and fats processing is aimed to improve the overall process, by reducing water consumption, increase the yield and the quality of the oil and improve its storage stability through efficient removal of phosphatides, also called gums. Lipase should be added to the aqueous phase in oil where it exerts its function by hydrolysing phospholipids; at the end it is removed as water based sludge.

The use of the lipase during the eggs processing is aimed to hydrolyse phospholipids, resulting in better emulsifying properties, to increase the thermo-stability of the egg yolks and to allowing the use of higher pasteurisation temperatures for sauces and dressing.

According to the applicant, the food enzyme is used at the minimum dosage necessary to achieve the desired reaction according to Good Manufacturing Practice (GMP). The dosage applied in practice by a food manufacturer depends on the particular process (see Table 2).

#### 4. Dietary exposure

The dietary exposure assessment is performed for the processes for which the food enzyme is intended to be used (Table 2). The human intake of foods produced with the food enzyme is that reported by the EFSA Comprehensive European Food Consumption Database<sup>11</sup>.

In the case of oils and fats processing, the maximum recommended dosage is up to 0.6 KLU/kg oils/fats, corresponding to 2.8 mg TOS/kg vegetable oil (Table 2). A mean consumption of vegetable oil in 17 countries of 1.19 g /kg body weight (bw)/day was taken into account; therefore, the intake resulted to be 0.0033 mg TOS/kg bw/day ( $(1.19 \times 10^{-3} \text{ kg vegetable oil /kg bw/day}) \times (2.8 \text{ mg TOS/kg vegetable oil})$ ).

In the case of egg processing, the maximum recommended dosage is 40 KLU/kg egg yolks, which corresponds to 184 mg TOS/kg egg yolks. In the EFSA Comprehensive European Food Consumption Database the mayonnaise was not reported, therefore, in order to consider a worst-case scenario, the consumption of prepared salads in Greece (2.31 g/kg bw/day) was taken into account. It was also assumed that 50 % of salads were mayonnaise and that it contains 10 % egg yolks treated with food enzyme, which means 0.12 g egg yolks kg bw/day treated with the food enzyme. The intake was then calculated to be 0.022 mg TOS/kg bw/day ( $(0.12 \times 10^{-3} \text{ kg egg yolks/kg bw/day}) \times (184 \text{ mg TOS/kg egg yolks})$ ).

Finally, by adding the intakes calculated in both processing, the estimated dietary exposure can be calculated to 0.025 mg TOS/kg bw/day.

In case the food enzyme is proposed for products particularly designed for infants or young children, *ad hoc* conservative exposure estimates must be made taking specifically into account these population groups. Otherwise, the very conservative approach described above, is considered to cover both adults and children.

#### 5. Toxicological data

The toxicological assays were performed with a food enzyme (batch PPW 7023, see Table 1) representative of the other three food enzyme batches.

##### *Genotoxicity testing*

In order to investigate the potential to induce gene mutations in bacteria, an Ames test was performed according to OECD Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP) in four strains of *Salmonella typhimurium* (TA1535, TA100, TA1537, TA98) (treat and plate assay) and *Escherichia coli* WP2uvrA (plate incorporation assay), in the presence or absence of metabolic activation by S9 mix. Two experiments were carried out using six different concentrations of the food enzyme, appropriate positive controls and deionised water as a negative control. The highest concentration was 5 000 µg dry matter (ca. 3 650 µg TOS) per ml incubation mixture (treat and plate assay) or per plate (plate incorporation assay). All positive controls induced significant increases in revertant colony numbers, confirming the sensitivity of the tests and the efficacy of the S9 mix, while the negative controls were within the normal ranges. Upon treatment with the food enzyme there was no increase in revertant colony numbers. Therefore, it was concluded that the food enzyme has no mutagenic activity, under the conditions employed.

The *in vitro* chromosome aberration test carried out according to the OECD Test Guideline 473 (OECD, 1997b) and following GLP. Cultured human peripheral blood lymphocytes, the division of which was stimulated with phytohaemagglutinin (PHA), were treated with purified water (negative control), the food enzyme or appropriate positive controls (4-nitroquinoline 1-oxide or

11 EFSA Comprehensive European Food Consumption Database <http://www.efsa.europa.eu/en/datexfoodcdb/datexfooddb.htm>

cyclophosphamide in the absence or the presence of the S9 mix, respectively). Two experiments were performed. In the first experiment, applying 3 + 17 hours treatment, the cultures were exposed to the food enzyme (3 200, 4 000 and 5 000 µg food enzyme/ml, corresponding to ca. 300, 380 and 475 µg TOS/ml) for 3 hours either in the presence or the absence of the S9 mix. In the second experiment, the concentrations of the food enzyme tested were 3 613, 4 250 and 5 000 µg food enzyme/ml (corresponding to ca. 340, 400 and 475 µg TOS/ml); a 20 + 0 hours treatment, where cultures were exposed to the food enzyme for 20 hours without the S9 mix and a 3 + 17 hours treatment with the S9 mix, were applied. In all cases the cells were harvested 20 hours after the beginning of treatment. Only cells with 44 to 46 chromosomes were considered. When tested in the presence of S-9 mix, the highest concentration of the food enzyme induced 1 % and 0 % mitotic inhibition in experiment 1 and 2, respectively, whereas 3 % mitotic inhibition were observed in the absence of S-9 mix in experiment 1 but 22 % mitotic inhibition in experiment 2. These findings imply that prolonged treatment with the food enzyme at high concentrations affects the cell cycle. For all food enzyme concentrations used, the frequency of cells with chromosomal aberrations was similar to that of negative controls (values of  $p \leq 0.05$  were considered as significant) except for one replicate of the highest concentration in experiment 1 in the absence of S-9 mix, where a small increase in cells with chromosomal aberrations was found. However, because this marginal increase was not observed in the other replicate and in experiment 2, it is not considered to be of biological significance. It was concluded that the food enzyme did not induce chromosomal aberrations in cultured human peripheral blood lymphocytes when tested up to 5 000 µg food enzyme/ml (corresponding to 475 µg TOS/ml) under the experimental conditions employed.

#### *Repeated dose toxicity testing*

A 90-day subchronic oral toxicity study was performed according to OECD Test Guideline 408 and following GLP (OECD, 1998). Four groups of 10 male and 10 female CD rats were given by gavage a dose of 10 ml/kg bw/day tap water (negative control) and three doses of the food enzyme equivalent to 100, 340 and 1020 mg TOS/kg bw/day.

One female receiving the highest dosage died during the 7<sup>th</sup> week of treatment. The macroscopic examination revealed perforation of the oesophagus and fluid in the thorax; the microscopic examination revealed oesophagitis, pleuritis and epicarditis. Because of these findings, the death was attributed to an injury of the oesophagus during administration of the test substance.

Salivation was observed in some females and males after completion of the dosing, in particular in one male treated with the highest dose on one day during the 4<sup>th</sup> week.

In haematological examination, a slight statistically significant increase in the Mean Cell Volume (MCV) in females treated with the lowest and the highest dosages was noticed. An increasing trend in the neutrophils was also observed in both sexes without however statistical significance in any group.

In blood chemistry, a slight decrease of total cholesterol (not statistically significant) and albumin (statistically significant) concentrations and a statistically significant low albumin to globulin ratios in males receiving the highest dose were observed. Statistically significant lower calcium concentrations in males treated with the lowest and the highest doses, and statistically significant higher sodium and chloride concentrations in females receiving the middle and the highest dosages were also noted. The statistically significant decrease on calcium and albumin in the high dose males' group in combination with some minor histopathological alterations in thymus were indicative of adverse effects at the highest dose level. Consequently, the Panel derived a NOAEL on the mid dose level of 340 mg TOS/kg bw/day.

## **6. Allergenicity**

Potential allergenicity of lipase was assessed by comparing its amino acid sequence with those of known allergens according to the EFSA Scientific opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified

Organisms (EFSA GMO Panel, 2010). Using higher than 35 % identity in a window of 80 amino acids as the criterion, no match was found. No food allergic reactions to lipase have been reported in the literature.

Consequently, the CEF Panel considers that the likelihood of food allergic reactions to this lipase produced with this genetically modified strain of *A. oryzae* is low and therefore does not raise safety concern.

## 7. Discussion

The parental strain *A. oryzae* A1560 has a long history of use for the production of food enzymes. The recipient strain, BECh2, was developed from the parental strain through a series of modification steps including classical mutagenesis and genetic modifications. The *A. oryzae* production strain NZYM-FL contains the chimeric lipase gene in multiple copies randomly integrated into the genomic DNA as part of the plasmid vector and the genetic modification has been proved to be stable. The introduced trait is well-known and does not trigger a safety concern. No sequences that cause concern were introduced. Neither the production strain nor the recombinant DNA were detected in the final products by methods considered adequate by the CEF Panel.

The information provided on the manufacturing of the food enzyme, i.e. the fermentation conditions and the steps employed for isolation and purification, is considered sufficient. The available compositional data, including experimental evidence of the absence of potential contaminants such as mycotoxins, sufficiently demonstrate the identity and the purity of the food enzyme. The reported batch-to-batch variability is considered acceptable.

Dietary exposure estimates were calculated by assuming that the food enzyme is used at its maximum recommended dosage and all the added food enzyme remains in the final food. Based on these assumptions and considering the total intake (Section 4), the estimated dietary exposure results to be 0.025 mg TOS/kg bw/day.

The food enzyme produced with the genetically modified *A. oryzae* strain NZYM-FL did not induce gene mutations in bacteria with or without metabolic activation. Neither did it induce chromosome aberrations in cultured human blood lymphocytes. Therefore, there is no concern with respect to genotoxicity.

A comparison of the NOAEL (340 mg TOS/kg bw/day) from the 90-day study with the estimated dietary exposure, calculated to be 0.025 mg TOS/kg bw/day, results in a Margin of Exposure (MOE) of 13 600, which is found sufficient.

The CEF Panel considers that the likelihood of food allergic reactions to this lipase from this genetically modified strain of *A. oryzae* is low and therefore does not raise safety concerns.

## CONCLUSIONS

Based on the genetic modifications performed, the manufacturing process, the compositional and biochemical data provided and the toxicological studies, the food enzyme “Lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL)” does not raise safety concern under the intended conditions of use.

## DOCUMENTATION PROVIDED TO EFSA

1. Dossier “Lipase from a genetically modified strain of *Aspergillus oryzae* (strain NZYM-FL)”. February 2013. Submitted by Novozymes A/S.
2. Additional information received by Novozymes A/S on August 2013.

## REFERENCES

- Blumenthal CZ, 2004. Production of toxic metabolites in *Aspergillus niger*, *Aspergillus oryzae*, and *Trichoderma reesei*: justification of mycotoxin testing in food grade enzyme preparations derived from the three fungi. *Regulatory Toxicology and Pharmacology*, 39, 214-228.
- EFSA Panel on Genetically Modified Organisms (GMO), 2010. Scientific opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feed. *EFSA Journal* 2010;8(7):1700, 168 pp. doi:10.2903/j.efsa.2010.1700
- EFSA Panel on Genetically Modified Organisms (GMO), 2011. Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use. *EFSA Journal* 2011;9(6):2193, 54 pp. doi:10.2903/j.efsa.2011.2193
- EFSA Panel on Biological Hazards (BIOHAZ), 2012. Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2012 update). *EFSA Journal* 2012;10(12):3020, 84 pp. doi:10.2903/j.efsa.2012.3020
- EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Panel of Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) on the Submission of a Dossier on Food Enzymes for Safety Evaluation by the Scientific Panel of Food Contact Material, Enzymes, Flavourings and Processing Aids. *The EFSA Journal* 2009; 1305, 1-26.
- FAO/WHO (Food and Agriculture Organization of the United States/World Health Organization), 2006. General specifications and considerations for enzyme preparations used in food processing in Compendium of food additive specifications. 67<sup>th</sup> meeting. *FAO JECFA Monographs* 3, 63-67. Available online: <ftp://ftp.fao.org/docrep/fao/009/a0675e/a0675e00.pdf>
- Lee LS, Bayman P and Bennett JW, 1991. Mycotoxins. In: *Biotechnology of Filamentous Fungi. Technology and Products*. Eds Finkelstein DB and Ball C. Butterworth-Heinemann, Stoneham, USA, 463-503.
- OECD, 1997a. Bacterial Reverse Mutation Test. Guideline 471, adopted 21.07.1997. Available online: [http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test\\_9789264071247-en;jsessionid=9zfgzu35paaq.x-oecd-live-01](http://www.oecd-ilibrary.org/environment/test-no-471-bacterial-reverse-mutation-test_9789264071247-en;jsessionid=9zfgzu35paaq.x-oecd-live-01)
- OECD, 1997b. *In vitro* Mammalian Chromosomal Aberration Test. Guideline 473, adopted 21.07.1997. Available online: [http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test\\_9789264071261-en](http://www.oecd-ilibrary.org/environment/test-no-473-in-vitro-mammalian-chromosome-aberration-test_9789264071261-en)
- OECD, 1998. Repeated Dose 90-day Oral Toxicity Study in Rodents. Guideline 408, adopted 21.09.1998. Available online: [http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents\\_9789264070707-en](http://www.oecd-ilibrary.org/environment/test-no-408-repeated-dose-90-day-oral-toxicity-study-in-rodents_9789264070707-en)

## ABBREVIATIONS

Afl	aflatoxin
AU	Anson Units
BGU	Beta-Glucanase Units
bw	body weight
CAS	Chemical Abstracts Service
CFU	Colony Forming Units
CPA	Cyclopiazonic acid
DNA	Deoxyribonucleic acid
EC	European Commission and Enzyme Commission
ECU	Endo Cellulase Units
EFSA	European Food Safety Authority
EINECS	European Inventory of Existing Commercial Chemical Substances
EU	European Union
FAO	Food and Agricultural Organisation
GLP	Good Laboratory Practice
GMM	Genetically Modified Microorganisms
GMO	Genetically Modified Organisms
GMP	Good Manufacturing Practice
PHA	Phytohaemagglutinin
IUBMB	International Union of Biochemistry and Molecular Biology
JECFA	Joint FAO/WHO Expert Committee on Food Additives
KA	Kojic acid
kDa	kilo Dalton
KLU	Kilo Lipase Units
KNU	Kilo Novo alpha-amylase Units
LC-MS/MS	Liquid Chromatography/tandem Mass Spectrometry
LU/g	Lipase Units per gran
MCV	Mean Cell Volume
MOE	Margin of Exposure
MS	Mass Spectrometry
NOAEL	No-Observed-Adverse-Effect Level
NA	Not Analysed
ND	Not Detected
NPA	$\beta$ -nitropropionic acid
OECD	Organisation for Economic Cooperation and Development
PCR	Polymerase Chain Reaction
QPS	Qualified Presumption of Safety
SDS-PAGE	Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis
TOS	Total Organic Solids
UV	Ultraviolet
WHO	World Health Organisation